Why the study?
Heart dysfunction after cytostatic drugs and monoclonal antibodies limits multiple myeloma treatment, and early diagnostic and prognostic tools for cardiovascular toxicity remain an unsolved problem.
Early diagnosis and monitoring of cardiovascular toxicity using imaging and biomarkers are essential in managing multiple myeloma patients undergoing polychemotherapy.
Cardiotoxicity may limit multiple myeloma therapy with cytostatics or antibodies; Level 5 evidence leaves open prospective risk-stratification studies.
Heart dysfunction that occurred after using cytostatic drugs and monoclonal antibodies may be a limit factor in the treatment of multiple myeloma. Side effects of chemotherapy include hypotension, hypertension, arrhythmias, conduction disturbances, pericarditis, thromboembolic events, heart failure, death.The risk of cardiotoxicity may be increased by some factors that include drug exposure, age, history of heart diseases, arterial hypertension, drug combination, previous radiotherapy or chemotherapy. It’s important to detect cardiovascular toxicity before the appearance of clinical signs of heart and vessel disturbance. The role of markers in the elicitation of risk groups of cardiovascular events is uncertain yet.Early diagnostics and definition of prognostic factors of cardiovascular toxicity appeared after polychemotherapy of oncohematological diseases are important and not solve problems. multiple myeloma, cardiovascular events, chemotherapy, diagnostics, prognostic factors.
No takes yet. Share an insight, caveat, or question.
Самура et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: